Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Founded by physician-scientists with expertise in cardiovascular signaling pathways, the company aims to transform the treatment landscape by targeting previously untapped biological mechanisms such as PDE9 and CaMKII. Headquartered in Burlington, Massachusetts, with a major research facility in Shonan, Japan, Cardurion leverages a strategic partnership with Takeda Pharmaceuticals and a robust internal discovery engine. The company is currently advancing multiple first-in-class candidates through mid-to-late-stage clinical trials, supported by significant backing from leading life sciences investors like Bain Capital and Ascenta Capital.